SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a sharp sell-off as weak forward guidance and concerns over supply chain constraints and margin pressure overshadowed a revenue beat. Investors are debating whether this pullback is an overreaction to temporary headwinds or a necessary correction for a stock that recently traded at elevated valuations.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors react to a powerful earnings report where AWS cloud revenue growth accelerated to its fastest pace in years, fueling confidence that massive AI infrastructure spending is finally translating into tangible enterprise demand. The community is actively debating the sustainability of this AI-driven expansion and closely monitoring management's commentary on capital expenditure and long-term profitability.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is facing intense volatility as investors weigh strong earnings and revenue beats against concerns regarding declining U.S. daily active users and uncertainty over Google's search traffic impact. The community remains deeply polarized, with many users and traders debating the platform's long-term monetization potential and content moderation policies versus the risks of AI-driven search disruption.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors digest a detailed CMC manufacturing update, with the community closely tracking the progress toward a Q4 BLA filing. Discussions are heavily focused on high institutional accumulation, potential partnership or buyout interest, and optimism regarding the company's regulatory path and lead pipeline asset.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure following a weak third-quarter outlook and the withdrawal of its full-year guidance, which has triggered a wave of analyst downgrades. The community remains deeply divided, with some investors aggressively buying the dip as a long-term value play, while vocal critics are pointing to slowing growth, monetization headwinds, and ongoing platform safety concerns.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently a focal point for investors as it navigates significant volatility following a major surge in share price, now drawing intense discussion around its critical role as a supplier of indium phosphide substrates for AI data center infrastructure. The community remains deeply divided, with bulls pointing to the company's multi-year supply agreements and growing backlog, while bears express skepticism regarding valuation and the company's exposure to geopolitical risks and export permit constraints.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending as investors weigh disappointing trial results from a cardiovascular study against the company's strong core growth in its GLP-1 obesity and diabetes portfolio. While the market reacted to the specific trial setback, community discussion remains focused on long-term execution, oral pill potential, and the belief that the stock price presents a buying opportunity amid broader pipeline progress.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is facing significant volatility following a weak quarterly earnings report that missed revenue and earnings expectations, triggering a wave of analyst downgrades. While some investors are monitoring potential developments around the Clarity Act as a long-term catalyst, community sentiment remains sharply divided between those betting on an institutional recovery and those concerned about the company's long-term sustainability amidst intensifying competition.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors react to a polarizing FDA Advisory Committee vote that supported the efficacy of its melanoma treatment, fueling intense debate over the reliability of the clinical data and the company's path to potential approval. The community is sharply divided, with bulls pointing to the positive committee sentiment and unmet patient need, while skeptics emphasize the significant regulatory hurdles, safety concerns, and the history of prior rejections.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS is seeing intense volatility and social media buzz as traders debate whether the recent semiconductor sector weakness is a temporary dip or a long-term structural shift. The community is actively discussing the impact of sector-wide circular financing concerns and potential margin calls, with many using the inverse ETF to hedge against or bet against high-growth chip stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.read more...

HC Wainwright Issues Pessimistic Outlook for CBIO Earnings

Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Crescent Biopharma in a note issued to investors on Monday, May 4th. HC Wainwright analyst M. Kapoor now forecasts that the biopharmaceutic...

Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3% - Here's Why

Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 8.3% - Here's Why...

Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell?

Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat...

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - What's Next...

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving Average - Time to Sell?

Crescent Biopharma (NASDAQ:CBIO) Share Price Passes Above 200 Day Moving Average - Should You Sell...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three h...

Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright

HC Wainwright decreased their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Inc.

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

CBIOCrescent Biopharma Inc.

Latest CBIO News